The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
LD sponsers with the big boys
https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fclinicalvirology.org%2Fwp-content%2Fuploads%2F2023%2F12%2FClinical-Virology-Network-May-2024-Programme.docx&wdOrigin=BROWSELINK
Good afternoon - LD in action
"
Launch Diagnostics LimitedLaunch Diagnostics Limited
1,706 followers1,706 followers
1h • 1 hour ago
The team from Launch are ready to welcome you at hashtag#cvn2024 taking place at Austin Court in Birmingham today and tomorrow.
We look forward to speaking with existing contacts and making new connections, come and see us to discuss the solutions available from Launch Diagnostics Ltd for your service."
https://www.linkedin.com/feed/update/urn:li:activity:7198626699314352128/
https://clinicalvirology.org/events/
Accept many here not impressed with Avacta Group management - delivery & execution - funding - diagnostics purchases , that can/will be fixed in due course .
It is not the current SP or more share dilution that is important to me but the amazing fact -Avacta have already achieved :
"The first of the pre|CISION molecules, AVA6000, has achieved clinical proof-of-concept."
"The Avacta pre|CISIONTM platform is a proprietary warhead delivery system based on a tumour-specific protease that is designed to concentrate highly potent warheads in the tumour microenvironment while sparing normal tissues."
This is what really matters & folks should look forward to ---- a win for cancer patients ,clinicians & eventually a huge payout for shareholders - as i keep repeating the value in the proprietary assets IP.
Meantime HCI Loan will continue to be paid in shares until a substantial deal is done that fully supports Therapeutics pipeline , then loan can be settled in full - Sorry might be more pain before gain , but will be worth the wait IMO.
Good luck everyone .
Yes Rambo Lena must see some merit in joining LD . Might still be future asset value to be gained , do hope so for all the LD/Coris staff employed . Seem have a wide range of proven IVD products to distribute & sell .
Be good they get a chance to make the business work and prove the doubters wrong .
https://avacta.com/diagnostics/
SB listed here :
https://avacta.com/precision/therapeutics-team/
Note Dr. Cathy Fiatte & Dr. Lena Kastl photo
https://avacta.com/diagnostics/diagnostics-team/
https://avacta.com/people/lena-kastl/ 1 2024-05-20 07:57 +00:00
https://avacta.com/people/cathy-fiatte/ 1 2024-05-20 07:57 +00:00
Principal Investigator: Professor Udai Banerji : They can complinent each other - room for all treatments .
Courtesy twitter :
-------------------------
"New frontiers in exploiting stroma for therapy. FAP directed precision medicine. Phase I of AVA600 showing tolerability, plasmas/tumour PK and clinical proof of concept response in FAP high tumours. Abstract CT188 #AACR2024
@ICR_London
@royalmarsdenNHS
@ECMC_UK
-----------
nick kaulbach
@nickkaulbach
Thank you for posting. Can I ask where you believe Peptide Drug Conjugates could be superior to ADC’s?
------------------
Reply
udaibanerji
@udai_banerji
·
Apr 9
Will be complimentary but not necessarily competing. Does not need to be internalised by target, often have cytotoxics that you need to be circulating for a longtime, very interesting combinations etc. Still a lot of space for such drugs to find an indication."
https://x.com/nickkaulbach/status/1777783735968055704
https://x.com/udai_banerji/status/1777778199289581619
Thought i would try email questions to Avacta CEO . Status of two weekly study & Spotlight Series -Episode 3 etc - So far no reply .
-------------
Meantime LD continue to boost products :
"This month is coeliac awareness month."
https://www.linkedin.com/feed/update/urn:li:activity:7197222958333837312/
1,705 followers1,705 followers
19h • 19 hours ago
This month is coeliac awareness month.
With a prevalence of 1 in 100, hundreds of thousands of people in the UK have coeliac disease, but only 36% have received a diagnosis.
It is therefore estimated that 500,000 people in the UK are living with undiagnosed coeliac disease. Coping with unexplained health problems without diagnosis can have significant effects on both mental and physical health.
NICE guideline NG20 states; when healthcare professionals request serological tests to investigate suspected coeliac disease in young people and adults laboratories should test for IgA tissue transglutaminase (tTG) as the first choice. With the HOB BioCLIA 500 or BioCLIA 6500 testing for IgA (or IgG) anti-tTG is quick and easy, with a large range of further autoimmune assays also available on the platforms.
Contact your local Launch representative or go to our website for further information.
https://lnkd.in/esUcttq
https://www.coeliac.org.uk
https://lnkd.in/d329Vfg
Good Morning : LD being proactive
https://www.launchdiagnostics.com/product/crypto-giardia-combi-eia/
https://www.linkedin.com/feed/update/urn:li:activity:7196878794434007042/
----------
Outbreak Alert: Cryptosporidium in Brixham Water Supply
Residents in parts of Brixham have been advised to boil their drinking water following the confirmation of 22 cases of cryptosporidiosis in the area.
South West Water has detected small traces of the parasite cryptosporidium in the water supply in Devon. As this situation evolves, the risk of further cases remains if the contamination continues.
At Launch Diagnostics, we understand the urgency and importance of addressing waterborne diseases like cryptosporidiosis promptly and accurately.
Our Crypto ELISA kits provide a reliable solution for detecting cryptosporidium, helping to identify and manage outbreaks effectively.
In these challenging times, accurate diagnostics are crucial.
For more information on our Cryptosporidium ELISA kits and how we can support healthcare providers and laboratories please visit our website or contact our team directly.
https://lnkd.in/eBjh4T5D
Clonit use a number of distributors world wide : LD cover UK-France -Benelux :
https://www.clonit.it/en/world-wide-distributors/
FYI :
"Launch Diagnostics LimitedLaunch Diagnostics Limited
1,692 followers1,692 followers
55m • 55 minutes ago
The Clonit Quanty assays from Launch Diagnostics Ltd for transplant related pathogens provide accurate quantitation of viruses such as Adenovirus, CMV, EBV, BKV, HHV6 and many more. These assays provide precise and sensitive measurement of viral loads, crucial for monitoring disease progression and treatment efficacy in post transplant patients.
Their high sensitivity enables the detection of even low viral concentrations, facilitating early intervention and improved patient outcomes. Moreover, the assays' quantitative nature allows for precise tracking of viral loads over time, aiding clinicians in making informed decisions regarding therapeutic strategies.
The assays are compatible with many extraction and PCR platforms which you may already have available, allowing these systems to be fully utilised. Many laboratories currently send some or all of these assays to reference labs, and repatriation can offer increased control, decreased turnaround time and cost savings.
For more information on the Clonit quality PCR’s, please visit:
https://www.launchdiagnostics.com/product/clonit-transplant-pcrs/
https://www.launchdiagnostics.com/manufacturer/clonit/
https://lnkd.in/eGZ3ZyS7"
FYI
https://www.linkedin.com/company/launch-diagnostics/
Launch Diagnostics LimitedLaunch Diagnostics Limited
1,678 followers1,678 followers
2d • Edited • 2 days ago
On the 4th April 2024 the Medicines and Healthcare products Regulatory Agency (MHRA) approved the combined antibiotic cefepime/enmetazobactam (brand name Exblifep) to treat adult patients with complicated infections of the urinary tract and certain types of pneumonia.
Enmetazobactam blocks the action of beta-lactamases, allowing cefepime to act against bacteria that would otherwise be resistant.
We are pleased to announce the addition of cefepime-enmetazobactam to the Liofilchem MTS (MIC Test Strip) range.
Currently available as RUO device.
Launch Diagnostics is the exclusive distributor of Liofilchem's portfolio in the UK.
For all your AMR testing solutions, head over to our website: www.launchdiagnostics.com, or contact enquiries@launchdiagnostics.com
hashtag#microbiology hashtag#antimicrobialstewardship hashtag#antimicrobialresistance
hashtag#AMR hashtag#NHS hashtag#antibiotics hashtag#antimicrobials hashtag#patientcare
Good Morning : Thanks for sharing Knotagain
Avacta Peptide Drug Conjugates – Multiple advantages over traditional ADC
https://avacta.com/precision/precision-drug-conjugate-pdc/
--------- "price/earnings multiples" very impressive . Avacta need to list in USA .
"Daiichi Sankyo is expected to be the ADC leader in 2028 with nearly $10bn of sales, according to Evaluate. It trades on a price/earnings multiple of 50 times, the kind of hefty multiple normally associated with obesity stocks. Novo Nordisk is on a 37 times multiple and Eli Lilly on 59 times. Some estimates of the long-term market potential invite parallels with obesity drugs. Morgan Stanley reckons the ADC market could eventually be worth more than $140bn."
Good Morning
Quite a few companies using radioligand therapies mentioning FAP :
Nice tweet from Marty McFly this morning
@Blueberrymgmnt
·
51m
#AVCT
Game changer.
Quote
Perspective Therapeutics
@Perspective_Tx
·
16h
Did you know - Fibroblast Activation Protein-α (FAP) is a potential game-changer in #cancer therapy? Primarily expressed on tumor stroma cells, FAP represents a promising target across multiple cancer types. "
https://twitter.com/Blueberrymgmnt/status/1789204423270400400
-----------------------
Quote below comes from this scientific paper conclusions
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954613/
"Attempts should be made to find more effective ways to manage DOX toxicity. As a result, DOX must be loaded into a special vehicle and delivered to specific tumor sites, minimizing toxicity while maximizing the therapeutic benefits. "
Avacta have a solution "pre|CISIONTM Concentrating highly potent warheads in the tumour microenvironment "
So many opportunities to work with drug partners ,
Exciting times good luck everyone ,
As per Thompi reamarks "Did you get under No.2 on the slide that there is a big pharma contract in progress? And also something about a spin-out under No.5?"
This is the last slide in English courtesy of twitter comments : -
"The presentation is in Korean. But the Google Lens translate of the final slide is interesting, including big pharma contract in progress and a spin out?
https://twitter.com/sandyradders/status/1788549727245447480/photo/1
I for one appreciate AS efforts on shareholfers behalf ,personally feel sad that he has left the company without completing has life long ambition.
Wish him the very best .
https://www.linkedin.com/in/alastair-smith-1b4b9111/recent-activity/all/
--------------------------
"Linkedin
Life Sciences ExecutiveLife Sciences Executive
Self-employedSelf-employed
Apr 2024 - Present · 2 mos
------------------
"Scientist by training and founder of Avacta Group plc, an AIM listed life sciences company.
Extensive experience of building early stage businesses within Avacta Group during nearly 20 years as a public company CEO. Excellent communicator and presenter of growth company investment opportunities. An effective team builder and business leader capable of delivering growth, and change when necessary, whilst maintaining a strong and positive culture within a business.
Significant management, strategic planning and transactional experience having led the public and private M&A activities of the Group since the IPO on AIM which was completed via a reverse merger.
Well known in the UK public markets, a respected and trusted executive with many years experience of investor relations in the UK, Europe and US. Successfully delivered multiple follow-on fund raisings for the Group totalling over £200m.
A scientist by training with a degree and PhD in Physics from Manchester University. Following a period of working in the US, returned in 1995 to take up an academic position at Leeds University. Became Professor of Molecular Biophysics at the age of 38, and over a ten years period, through close collaboration with life scientists, built one of the leading biophysics research groups in Europe before leaving an academic career in 2007 to focus full time on delivering value to Avacta shareholders.
Passionate about building successful life science businesses based on world-class science and great teams."
FYI - 08 May 2024
Vacancies List
Therapeutics
Medicinal Chemist
Scientist/Senior Scientist (Immunology)
Diagnostics
No current vacancies
---------------------------------
https://avacta.com/careers/scientist-senior-scientist-immunology/
https://avacta.com/careers/medicinal-chemist/
https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Favacta.com%2Fwp-content%2Fuploads%2F2024%2F05%2FScientist-Snr-Immunology-April-2024-CAREERS-PAGE.docx&wdOrigin=BROWSELINK
https://avacta.com/wp-content/uploads/2024/05/Avacta-Medicinal-Chemist-May-2024-FINAL28.pdf
"Avacta Diagnostics expected to be overall EBITDA positive in second half of 2024 and cash generative 2025"
Anyway good or bad decision , it happened ,still on Avacta Balance sheet , so worthwhile making it work .
Perhaps Avacta might sell Coris & LD as seperate entities ?
@ Bella6532 : AMR Global issue not just the UK : Avacta well placed with Coris /LD :
"Anti-Microbial Resistance concern pushed Coris BioConcept to develop a range of assays (RESIST) for rapid detection of antibiotic resistance mechanisms. Aside of this range, another innovative approach for 3GC detection was recently launched with a front line test: BL-RED.
This R&D expertise is ideally suited for “on demand” production of innovative solutions in a rapidly changing world that calls for cutting edge biotechnology to take us forward into a healthy future.
All Coris BioConcept’s products fulfil the CE marking requirements with an ISO 13485 certification and they are used in over 60 countries all over the world.
Coris BioConcept is now part of Avacta Group."
----------------
"Coris BioConcept is a leading expert in the field of rapid diagnostics kits. Based in Belgium and established in 1996, the company develops, produces and markets diagnostic kits, mainly for the detection of human infectious pathogens (bacteria, virus and parasites), and for the detection of antibiotic resistance markers.
These rapid tests are based on the immunochromatographic (also known as lateral flow), the isothermal LAMP and the electrochemical technologies and are extensively used in microbiology laboratories worldwide.
Coris BioConcept is currently involved in multiple collaborative international projects (including Belgian and/or European grants) for the development of new rapid diagnostic assays, with focus on antimicrobial resistance and neglected tropical and emerging diseases.
This R&D expertise is ideally suited for the “on-demand” development or production of innovative solutions in a rapidly changing world that calls for cutting edge biotechnology to take us forward into a healthy future.
All Coris BioConcept’s products fulfill the CE marking requirements and the company is also certified ISO 13485.
--------------